C-type Lectin Receptors for Tumor Eradication: Future Directions

Cancers

Ingeborg Streng-Ouwehand¹  Wendy W. J. Unger¹ 

[1] Department of Molecular Cell Biology and Immunology, VU University Medical Center, P.O. Box 7057, 1007 MB Amsterdam, The Netherlands;

关键词: dendritic cells;    glycans;    antibodies;    DC-targeting;    immunotherapy;   

DOI  :  10.3390/cancers3033169

来源: mdpi

【 摘 要 】

Dendritic cells are key regulators in directing immune responses and therefore are under extensive research for the induction of anti-tumor responses. DCs express a large array of receptors by which they scan their surroundings for recognition and uptake of pathogens. One of the receptor-families is the C-type lectins (CLR), which bind carbohydrate structures and internalize antigens upon recognition. Intracellular routing of antigen through CLR enhances loading and presentation of antigen through MHC class I and II, inducing antigen-specific CD4⁺ and CD8⁺ T-cell proliferation and skewing T-helper cells. These characteristics make CLRs very interesting targets for DC-based immunotherapy. Profound research has been done on targeting specific tumor antigens to CLR using either antibodies or the natural ligands such as glycan structures. In this review we will focus on the current data showing the potency of CLR-targeting and discuss improvements that can be achieved to enhance anti-tumor activity in the near future.

【 授权许可】

CC BY   
© 2011 by the authors; licensee MDPI, Basel, Switzerland.